# Cytonus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytonus-therapeutics

- Industry: Biotechnology
- Headquarters: Carlsbad, US
- Website: www.cytonus.com/
- Total disclosed funding: $12M
- Latest round: Series A (Oct 27, 2023)
- Investors on record: 6

## About

Founded in 2018 and based in California, US, Cytonus Therapeutics, Inc., operates as a biotechnology company that offers a drug delivery platform called the Cargocyte. The company was founded by its CEO, Remo Moomiaie-Qajar. In October 2023, Cytonus Therapeutics, Inc. raised USD 11.7 million in series A funding led by Partners Investment, with participation from investors Proxima Ventures, Gemseki Inc., and Creative Ventures.

Cytonus offers a drug development and delivery platform that provides traditional drug administration methods and improves the success rate of therapeutic interventions.

The company employs a pragmatic shift by combining artificial intelligence (AI), synthetic biology, and drug delivery to create therapeutics by utilizing a synthetic biology-delivery platform called the Cargocyte™.

The company plans to use the October 2023 funding to keep expanding its product pipeline and portfolio.

## Funding rounds

- Series A, Oct 27, 2023, $12M — Wilson Sonsini Goodrich & Rosati, Proxima Ventures, Partners Investment, Creative Ventures, Gemseki Inc., KreaMedica Inc.

## Investors

- Wilson Sonsini Goodrich & Rosati — Series A
- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Series A
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series A
- Creative Ventures (https://capitalatlas.ai/funds/creative-ventures) — Series A
- Gemseki Inc. — Series A
- KreaMedica Inc. — Series A